Teri Lawver

Ms. Lawver joined Celldex in November 2025 as Senior Vice President, Chief Commercial Officer. Prior to joining Celldex, Ms. Lawver was Principal and Owner of Thera Lifescience Advisors, where she was a strategic advisor to CEOs and investors at pioneering life science and health technology companies. Ms. Lawver has overseen multiple first-in-class portfolio advances and blockbuster launches in immunology and inflammation, including pivotal indications for REMICADE® (infliximab), STELARA® (ustekinumab), and TREMFYA® (guselkumab). Previously, Ms. Lawver was Chief Commercial Officer at Dexcom, Inc. where she was responsible for $4B in annual revenue and 1900 employees across 50 countries. Prior to that, Ms. Lawver was an executive at Johnson & Johnson where she led significant and diverse global business units over her 20-year tenure, culminating as Worldwide Vice President for Janssen Immunology. She joined J&J through Centocor, where she was responsible for launching the industry’s first biologic therapies in the gastroenterology space. Before J&J, Ms. Lawver was an Associate Principal at McKinsey & Company, and leader in the Firm’s Healthcare Practice. She began her career as a Derivatives Analyst at Bloomberg Financial Markets.  She currently serves on the Board of Directors of Altimmune, Inc. Ms. Lawver holds a B.S. in Linguistics from Georgetown University and an M.B.A. from Duke University’s Fuqua School of Business.